Gene Electrotransfer to Muscle With Plasmid AMEP in Patients With Disseminated Cancer

Metastatic Malignant Neoplasm Clinical Trial

Official title:

Gene Electrotransfer to Muscle With Plasmid AMEP in Patients With Disseminated Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01664273
• Other study ID #: AA 1201
• Status: Terminated
• Phase: Phase 1
• First received: July 16, 2012
• Last updated: June 19, 2014
• Start date: July 2012
• Est. completion date: May 2015

Study information

• Verified date: June 2014
• Source: Copenhagen University Hospital at Herlev
• Contact: n/a
• Is FDA regulated: No
• Health authority: Denmark: National Board of Health
• Study type: Interventional

Clinical Trial Summary

Gene transfer by electroporation (gene electrotransfer) uses short electric pulses to transiently permeabilise the cell membrane enabling passage of plasmid DNA into the cell cytosol. It is an efficient non-viral method for gene delivery to various tissues. In this phase I dose-escalating study, patients will be treated with intramuscular gene electrotransfer of plasmid AMEP. Plasmid AMEP encodes protein AMEP which bind to α5β1 og αvβ3 integrins. Primary end point of the trial is safety and secondary end points are efficacy, pharmacokinetics and evaluation of potential discomfort associated with the treatment procedure using VAS (Visual Analogue Scale).

Description:

Cohorts of 3 patients will be treated with increasing doses of plasmid AMEP. Up to 12 patients will be treated.

Treatment procedure: Local anesthetic is applied to m. quadriceps femoris (thigh muscle) and the skin. An incision of the skin is performed followed by dissection until the muscle is exposed. The surgical procedure is performed by plastic surgeons.

Plasmid AMEP is injected intramuscularly and immediately followed by application of electric pulses via a needle electrode inserted into the muscle. A combination of one high voltage pulse (700V/cm, 100 µs) followed by one low voltage pulse (80 V/cm, 400 ms) will be applied. The wound is sutured and a dressing is applied. Treatment procedure is estimated to 30 minutes.

All patients are hospitalized for 24 hours after treatment for the purpose of evaluation of vital signs, physical examination, AE and SAE recording and pharmacokinetics sampling (blood and urine).

Blood biochemistry including LDH and CK is taken 24 hours post treatment. ECG will be taken before and after treatment. Patients score discomfort or pain from treated area using VAS.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 7
• Est. completion date: May 2015
• Est. primary completion date: May 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age > 18 years.

• Performance status < 1 (ECOG).

• Histologically confirmed malignant tumor (solid tumor) of any histology,

• Metastatic disease. Patients with asymptomatic brain metastases are eligible.

• Patient should have been offered standard treatment. Patient is eligible if no standard treatment is available or if the patient does not wish to receive standard treatment.

• Life expectancy = 3 months.

• Measurable disease defined as at least one measurable lesion according to RECIST 1.1

• Patient should have adequate organ function:

• Adequate bone marrow function: Neutrophil count = 1.0 x 109/l (= grade 2 CTCAE 4.0); Platelet count = 75 x 109/l (< grade 2 CTCAE 4.0); Hemoglobin = 6,0 mmol/l.

• Liver: ALAT or ASAT < 3 ULN (< grade 2 CTCAE 4.0); Bilirubin = 1,5 ULN (< grade 2 CTCAE 4.0); APTT within normal range; INR = 1,2 (< grade 1 CTCAE 4.0)

• Kidney: Plasma creatinin = 1.5 ULN (< grade 2 CTCAE 4.0)

• At least 4 weeks since any anti-cancer treatment.

• Men and women of reproductive age must use effective contraception during the study and at least 6 months after administration of plasmid AMEP.

• Patient should be able to understand the participant information and able to comply with protocol requirements and scheduled visits.

• Signed informed consent.

Exclusion Criteria:

• Allergy to the anaesthetic used.

• Clinical signs of active infection.

• Implanted pacemaker, defibrillator or any other implanted electronic device.

• Participation in other clinical trials involving experimental drugs or participation in a clinical trial within 4 weeks before initiation of study treatment.

• AMI (acute myocardial infarction), stroke or acute ischemic event within the last 6 months.

• Severe atherosclerosis, significant cardiovascular disease (NYHA III or IV) or significant arrhythmias.

• Systolic blood pressure above 180 mm Hg and/or diastolic blood pressure above 110 mm Hg. If BP >180/110 mm Hg medical correction is allowed and the patient can be included when BP < 180/110 mm Hg.

• Pregnancy and lactation.

• Clinically significant coagulopathy.

• Treatment with anticoagulant drugs.

• Other disorders which the investigator finds incompatible with participation in the study.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Metastatic Malignant Neoplasm
• Neoplasms
• Neoplasms, Second Primary

Intervention

Drug:
• Plasmid AMEP
Cohorts of 3 patients will received increasing doses of plasmid AMEP: 50 µg, 100 µg, 250 µg and 500 µg. Starting dose will be the lowest dose. Injection volume will remain constant at 200 µL. Once-only treatment and intra-individual dose escalation will therefore not occur.

Locations

Country	Name	City	State
Denmark	Depart. of Oncology, Copenhagen Universtiy Hospital Herlev	Herlev

Sponsors (1)

Lead Sponsor	Collaborator
Copenhagen University Hospital at Herlev

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of the trial treatment	Safety is evaluated by registration of adverse events (Adverse Events and Serious Adverse Events) using the CTCAE criteria version 4.0. Patients are seen in the out patient clinic once a week during the first month after treatment (at day 8, day 15, day 22, day 29) and 8 weeks after treatment. If no progression of the disease at 8 weeks, patients are seen at 12 weeks and then every three months until disease progression or death.	From treatment to last follow up, planned 8 weeks.	Yes
Secondary	Efficacy of the trial treatment	PET/CT scan will be evaluated using RECIST 1.1 (CT) and PERCIST (PET)	PET/CT scan 4 weeks, 8 weeks and 12 weeks after trial treatment.	No
Secondary	Pharmacokinetics	Measurements of plasma and urine plasmid AMEP concentrations. Measurements of plasma and urine protein AMEP concentrations	Pre-dose, 2, 6 and 24 hours after dose, day 8, 15, 22, 29 and 8 weeks after treatment.	No
Secondary	Discomfort associated with the treatment procedure	The patient completes VAS (Visual Analogue Scale) scores pain related to the treatment area at abovementioned time points.	Scoring 'immediately after treatment', '30 min after treatment' '6 hours after treatment' and 'pain in the past 24 hours', and day 8.	No
Secondary	Safety	MR scan of treated region (thigh muscle) in order to assess potential intramuscular edema or hematoma	Day after treatment and 14 days after treatment	Yes